JP2024530952A5 - - Google Patents

Info

Publication number
JP2024530952A5
JP2024530952A5 JP2024508322A JP2024508322A JP2024530952A5 JP 2024530952 A5 JP2024530952 A5 JP 2024530952A5 JP 2024508322 A JP2024508322 A JP 2024508322A JP 2024508322 A JP2024508322 A JP 2024508322A JP 2024530952 A5 JP2024530952 A5 JP 2024530952A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
independently
heterocycloalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530952A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/111050 external-priority patent/WO2023016434A1/en
Publication of JP2024530952A publication Critical patent/JP2024530952A/ja
Publication of JP2024530952A5 publication Critical patent/JP2024530952A5/ja
Pending legal-status Critical Current

Links

JP2024508322A 2021-08-10 2022-08-09 p53変異体を標的とする化合物 Pending JP2024530952A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/111797 2021-08-10
CN2021111797 2021-08-10
CNPCT/CN2021/125725 2021-10-22
CN2021125725 2021-10-22
CNPCT/CN2021/132409 2021-11-23
CN2021132409 2021-11-23
CNPCT/CN2022/073977 2022-01-26
CN2022073977 2022-01-26
CN2022097840 2022-06-09
CNPCT/CN2022/097840 2022-06-09
PCT/CN2022/111050 WO2023016434A1 (en) 2021-08-10 2022-08-09 Compounds targeting mutant of p53

Publications (2)

Publication Number Publication Date
JP2024530952A JP2024530952A (ja) 2024-08-27
JP2024530952A5 true JP2024530952A5 (enExample) 2025-06-24

Family

ID=85199878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508322A Pending JP2024530952A (ja) 2021-08-10 2022-08-09 p53変異体を標的とする化合物

Country Status (15)

Country Link
US (1) US20240400591A1 (enExample)
EP (1) EP4384510A4 (enExample)
JP (1) JP2024530952A (enExample)
KR (1) KR20240062147A (enExample)
CN (1) CN117813295A (enExample)
AR (1) AR126747A1 (enExample)
AU (1) AU2022325357A1 (enExample)
CA (1) CA3228559A1 (enExample)
CL (1) CL2024000406A1 (enExample)
CO (1) CO2024001421A2 (enExample)
IL (1) IL310653A (enExample)
MX (1) MX2024001870A (enExample)
TW (1) TW202322796A (enExample)
UY (1) UY39890A (enExample)
WO (1) WO2023016434A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
AU2023213949A1 (en) 2022-01-27 2024-07-25 Pmv Pharmaceuticals, Inc. Deuterated compounds for restoring mutant p53 function
CN119968361A (zh) * 2022-08-22 2025-05-09 北京加科思新药研发有限公司 靶向p53 Y220突变体的化合物
TW202435861A (zh) * 2022-12-08 2024-09-16 大陸商北京加科思新藥研發有限公司 靶向p53突變體的化合物
WO2024238404A2 (en) * 2023-05-12 2024-11-21 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2024263573A1 (en) * 2023-06-19 2024-12-26 Board Of Regents, The University Of Texas System Combination therapy methods for treating tp53-y220c mutant and tp53 wildtype leukemias
CN121693500A (zh) * 2023-08-09 2026-03-17 德睿智药(苏州)新药研发有限公司 用于调节p53功能的新型杂环类化合物
WO2025055856A1 (zh) * 2023-09-11 2025-03-20 长春金赛药业有限责任公司 p53-Y220C选择性小分子重激活剂化合物、药物组合物及其用途
WO2025082353A1 (en) * 2023-10-16 2025-04-24 Jacobio Pharmaceuticals Co., Ltd. Polymorphic forms of the compounds targeting mutant of p53 and uses thereof
WO2025011684A2 (zh) * 2023-10-20 2025-01-16 上海宇道生物技术有限公司 一类n-磺酰酰胺含氮稠杂环类化合物及其应用
WO2025085725A1 (en) * 2023-10-20 2025-04-24 Scorpion Therapeutics, Inc. Methods for treating a p53-associated cancer
WO2025151449A1 (en) * 2024-01-08 2025-07-17 Photys Therapeutics, Inc. Bifunctional p53-binding compounds and uses thereof
WO2025237199A1 (zh) * 2024-05-11 2025-11-20 上海齐鲁制药研究中心有限公司 含氮并环化合物、含其的药物组合物及其应用
WO2026025042A1 (en) 2024-07-26 2026-01-29 Dana-Farber Cancer Institute, Inc. P53 targeting compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002357193A1 (en) * 2001-12-19 2003-07-09 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
WO2004043903A1 (en) * 2002-11-05 2004-05-27 Eli Lilly And Company 3-aryloxy/ thio-2, 3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
EP3145512B1 (en) * 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
KR102868217B1 (ko) * 2016-02-19 2025-10-14 피엠브이 파마슈티컬스 인코포레이티드 돌연변이 p53 기능을 회복시키는 방법 및 화합물
CN109836434B (zh) * 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
DK4034104T3 (da) * 2019-09-23 2025-10-06 Pmv Pharmaceuticals Inc Metoder og forbindelser til genoprettelse af mutant p53-funktion
CA3183025A1 (en) * 2020-06-24 2021-12-30 Melissa Dumble Companion diagnostic tool for mutant p53 reactivating compounds
US20230049952A1 (en) * 2020-06-24 2023-02-16 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
WO2021262484A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2024530952A5 (enExample)
JP2024534610A5 (enExample)
RU2498983C2 (ru) Соединения фениламинопиримидина и их применения
RU2214997C2 (ru) Производные адамантана, способ их получения, фармацевтическая композиция и способ получения фармацевтической композиции
JP2021514001A5 (enExample)
JP2024520481A5 (enExample)
JP2013505903A5 (enExample)
JP2006515858A5 (enExample)
JP2023500611A5 (enExample)
JP2021529812A5 (enExample)
WO2018013597A4 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
RU2315041C2 (ru) Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения
JP2024529070A5 (enExample)
JP2020503297A5 (enExample)
JP2024512154A5 (enExample)
JP2017526636A5 (enExample)
JP2009544602A5 (enExample)
JP2024517498A5 (enExample)
JP2005508349A5 (enExample)
JP2024529527A5 (enExample)
JP2021535174A5 (enExample)
JP2020511452A5 (enExample)
JP2018525430A5 (enExample)
JP2024502175A5 (enExample)
JP2017534569A5 (enExample)